Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Mithra in 2018 - Erop of eronder

2.399 Posts
Pagina: «« 1 ... 99 100 101 102 103 ... 120 »» | Laatste | Omlaag ↓
  1. [verwijderd] 24 september 2018 07:36
    MITHRA FINALIZES CONTRACT FOR THE COMMERCIALIZATION OF ESTELLE® WITH SOUTH KOREAN WOMEN'S HEALTH LEADER HYUNDAI PHARM Liège, Belgium, 24 September 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce the finalization and signature of the contract with Hyundai Pharm, a South Korean Women’s Health leader, for an exclusive license and supply agreement to commercialize Estelle® in South Korea. The signature follows the binding Heads of Terms agreement previously announced on 5 June 20181. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate currently in pivotal Phase III trials in Europe and Russia as well as in the US and Canada. In August 2018, Mithra announced the positive top-line results from the Europe and Russia trial2 and the US/Canada trial remains on track to report top-line results in Q1 2019. Under the terms of the 20-year contract, Mithra will be eligible for upfront and milestone payments, Minimal Annual Quantities (MAQ) and further sales-related royalties. Moreover, Mithra will produce Estelle® for the South Korean market at its CDMO in Belgium. The South Korean contraceptive market is worth approximately EUR 36 million a year, with Combined Oral Contraceptives (COCs) accounting for EUR 27 million3. Hyundai Pharm is a top three Women's Health company in Korea, and the fastest growing with a CAGR of over 21% over the last three years4. The company has been steadily expanding its Women’s Health franchise, and aims to launch Estelle® as a fifth-generation oral contraceptive in South Korea. Hyundai Pharm is prepared to significantly invest in bringing Estelle® to market, with the clear intention to grow a still relatively small South Korean contraceptive market using our novel contraceptive. François Fornieri, CEO of Mithra, commented: “We are extremely pleased to have finalized the contract with Hyundai Pharm for the commercialization of Estelle® in South Korea. This contract is yet another step forward in Mithra’s strategy to identify and collaborate with Women's Health leaders around the world. Our focus is firmly on pursuing the best partners in the core territories of Europe and the US to maximize the potential of our blockbuster candidates.”

    Lees meer op: beursig.com/forum/viewtopic.php?f=4&a... voor meer informatie
  2. [verwijderd] 24 september 2018 08:34
    Landcruiser is hier duidelijk "de idioot van dienst". De koersen geven het gelijk zegt het. Van 12 naar 31 euro. Jaja... het heeft gelijk. Zijn typisch van die dingen (personen) die nutteloos zijn en dan door "stoer" te doen (lekker roken in dat autoke enz...) zichzelf een reden tot bestaan toemeten. Zielig dingetje...
  3. [verwijderd] 24 september 2018 08:44
    Altijd interessant om te zien dat er zoveel nieuwe namen op het forum komen bij hevige stijgingen en dalingen. Gelukkig vallen ze vanzelf weer weg bij rustig vaarwater.

    Back to business: Ik ken de Z-Koreaanse markt niet, maar deze partner is beursgenoteerd én gaat al een tijdje mee. Thoughts?
2.399 Posts
Pagina: «« 1 ... 99 100 101 102 103 ... 120 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.